Alpharadin extends overall survival in trial

New Topic Post Reply Printable Version
[ << Previous Thread | Next Thread >> ]

RobertC
Veteran Member


Date Joined May 2011
Total Posts : 1300
   Posted 6/6/2011 12:48 PM (GMT -6)   
Published on FierceBiotech (http://www.fiercebiotech.com)
Algeta shares spike on promising prostate cancer drug data
By john
Created Jun 6 2011 - 10:08am

Shares of Norway's Algeta spiked 36 percent this morning after the biotech's partner Bayer unveiled promising data on their castration-resistant prostate cancer treatment Alpharadin (radium-223 chloride). Median overall survival for patients with symptomatic bone metastases was 14 months compared to the 11.2 months registered among the standard therapeutic arm. And researchers stopped the trial so they could extend treatment to the placebo arm.

Robin Davison, a biotech analyst at Edison, told Reuters that the data amounted to "splendid news. There's almost no doubt that the product will now be approved. There's a very large increase of survival in the context of this particular cancer."

Prostate cancer treatments has been a hot field, with Dendreon leading the pack with Provenge. J&J followed up with an approval for Zytiga (abiraterone) and Medivation has a closely watched program for MDV3100.

"Around 90 percent of men with advanced prostate cancer have bone metastases, which are the main cause of disability and death in this disease," said Dr. Chris Parker, the principal investigator. "Advanced prostate cancer has a poor prognosis and treatment options are limited. Based on the observed survival benefit and its safety profile, Alpharadin may become an important treatment for patients with bone metastases from advanced prostate cancer."
Gleason (3+4) 7, PSA 5 in November 2011
cryoablation in January 2011.

logoslidat
Veteran Member


Date Joined Sep 2009
Total Posts : 5636
   Posted 6/6/2011 5:54 PM (GMT -6)   
Treatment is accelerating at an accelerating rate, what good news. Should have bought the stock, what?
Diagnosed 8/14/09 psa 8.1 66,now 67
2cores 70%, rest 6-7 < 5%
gleason 3+ 3, up to 3+4 @ the dub
RPP U of Wash, Bruce Dalkin,
pathology 4+3, tertiary5, 2 foci
extensive pni, prostate confined,27 nodes removed -, svi - margins -
99%continent@ cath removal. 1% incont@gaspass,sneeze,cough 18 mos, squirt @ running. psa std test reported on paper as 0.0 as of 12/14/10 ed improving
New Topic Post Reply Printable Version
Forum Information
Currently it is Thursday, April 19, 2018 7:28 PM (GMT -6)
There are a total of 2,953,398 posts in 324,001 threads.
View Active Threads


Who's Online
This forum has 162074 registered members. Please welcome our newest member, 831jen.
417 Guest(s), 9 Registered Member(s) are currently online.  Details
Froggy88, The Dude Abides, Pratoman, FLBeachgal, Busted1, F8, Quilter2015, xy123, Tall Allen